IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#955
Positioning
Market Dominance
Manufacturing
Medical Equipment
$205M
Kathleen S. Skarvan
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products. The company applies high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. It also provides single patient use SmartVest products for health care providers in the acute care setting.
Headcount
160
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ELMD ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ELMD Electromed, Inc. | 58 | 78 | 67 | 43 | 22.9x | 18.3x | 19.3% | 16.0% | 78.1% | 16.1% | 12.9% | 28.8% | 0.0% | 21.0x | $205M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Electromed, Inc. (ELMD) receives a "Hold" rating with a composite score of 57.5/100. It ranks #955 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Kathleen S. Skarvan
Chief Executive Officer
Labor Force
160
78
32
62
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for ELMD
HQ Base
NEW PRAGUE, Minnesota
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ELMD.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 78 | 87 | -9DRAG |
| MOMENTUM | 43 | 25 | +18ALPHA |
| VALUATION | 67 | 58 | +9ALPHA |
| INVESTMENT | 32 | 42 | -10DRAG |
| STABILITY | 62 | 52 | +10ALPHA |
| SHORT INT | 57 | 65 | -8DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 19.3% (sector -2.5%)
GM 78% vs sector 43%, OM 16% vs sector 1%
Capital turnover N/A, R&D intensity 1.7%
Rev growth 29%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns Electromed, Inc. a Hold rating, with a composite score of 57.5/100 and 3 out of 5 stars. Ranked #955 of 7,333 stocks, ELMD presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
ELMD earns a quality score of 78/100, indicating above-average business quality. The company reports a return on equity of 19.3% (sector avg: -2.5%), gross margins of 78.1% (sector avg: 42.5%), net margins of 12.9% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
ELMD's value score of 67/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 22.93x, an EV/EBITDA of 18.30x, a P/B ratio of 4.42x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
Electromed, Inc.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 28.8% vs. a sector average of 5.9% and a return on assets of 16.0% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ELMD is currently showing below-average momentum at 43/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 28.8% year-over-year, while a beta of 0.80 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 62/100, ELMD exhibits average financial resilience. Key stability metrics include a beta of 0.80 and a debt-to-equity ratio of 21.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 57/100 for ELMD suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 21.00x), micro-cap liquidity risk. With a $205M market cap (micro-cap), Electromed, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Electromed, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #955 of 7,333 overall (87th percentile). Key comparisons include ROE of 19.3% exceeding the -2.5% sector median and operating margins of 16.1% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ELMD currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Quality (78) vs Investment (32) — closing this gap could shift the rating.
EV/EBITDA 60% ABOVE SECTOR MEDIAN
ROE 877% BELOW SECTOR MEDIAN
Gross Margin 84% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate Electromed, Inc. (ELMD) as a Hold with a composite score of 57.5/100 at a current price of $23.19. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in quality (78th percentile) and value (67th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (32th percentile) and momentum (43th percentile) tempers our overall conviction. We assign a Narrow Moat rating (59/100), Low uncertainty, and Standard capital allocation.
Key items to watch: sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Electromed, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 57.5/100 places it at rank #955 in our full 7,333-stock universe. At $205M in market capitalization, Electromed, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 29%, though momentum at the 43th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 78% (+35.6pp vs sector) narrow to operating margins of 16% (+14.8pp vs sector) and net margins of 12.9%, yielding a gross-to-net conversion rate of 16%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $23.19, Electromed, Inc. is trading near fair value based on current fundamentals. Our value factor score of 67/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 22.9x (roughly in line with the sector median of 22.3x), EV/EBITDA of 18.3x (at a premium), P/B of 4.4x, P/S of 3.0x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
Gross margins of 78% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 19.3% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 29% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 67/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
A conservative balance sheet (21% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
We assign a Low uncertainty rating to Electromed, Inc.. The company exhibits strong financial stability with a beta of 0.80, conservative leverage (21% D/E), and a stability factor in the 62th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
We identify no major risk factors at this time. The company's stability factor sits at the 62th percentile with quality at the 78th percentile, both of which support our low-risk assessment. The absence of material leverage, profitability, or volatility concerns reduces the likelihood of a permanent capital loss scenario.
Key risk mitigants include: healthy gross margins of 78% provide a buffer against cost pressures; conservative leverage (21% D/E) limits balance sheet risk; above-average stability (62th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Electromed, Inc.'s capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 19.3%, and the balance sheet is managed within acceptable parameters (D/E: 21%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; Electromed, Inc. falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, Electromed, Inc. receives a Hold rating with a composite score of 57.5/100 (rank #955 of 7,333). Our quantitative framework assigns a Narrow Moat (59/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 56/100.
Our analysis supports a neutral stance on Electromed, Inc.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Electromed, Inc. a Narrow Moat rating with a composite moat score of 59/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Electromed, Inc. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 18.7/20.
The strongest moat sources are margin superiority (18.7/20) and growth durability (15.9/20). GM 78% vs sector 43%, OM 16% vs sector 1%. Rev growth 29%, 11yr history. These pillars form the core of Electromed, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0.6/20) and financial resilience (10.6/20). Capital turnover N/A, R&D intensity 1.7%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Electromed, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 78% providing a solid profitability foundation, operating margins of 16% reflecting effective cost management, robust top-line growth of 29% expanding the revenue base. The margin cascade from 78% gross to 16% operating to 12.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 78th percentile.
The margin profile shows gross margins of 78%, operating margins of 16%, net margins of 12.9%. Return metrics include ROE of 19.3% and ROA of 16.0%. Relative to the Manufacturing sector, gross margins are 35.6 percentage points above the sector median of 43%, and ROE of 19.3% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 21%, revenue growth of 29%. The sector median D/E is 0%, putting Electromed, Inc. at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
Even high-quality stocks face risks from valuation compression, competitive disruption, or macro shocks that are difficult to quantify in advance.
Above 50MA
37.18%
Net New Highs
+51081
Electromed, Inc. (ELMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Electromed Inc (ELMD) reports a robust 16.3% revenue growth and a 42.4% increase in operating income, while navigating declines in hospital channel revenue and expanding market reach.
Electromed (ELMD) Q2 2026 earnings call recap: record revenue, EPS growth, homecare momentum, payer expansion, and outlook for double-digit growth—read now.
Upgrades Northcoast Research upgraded the previous rating for Ecolab Inc (NYSE:ECL) from Neutral to Buy. Ecolab earned $1.10 in the second quarter, compared to $1.22 in the year-ago quarter. The stock has a 52-week-high of $237.38 and a 52-week-low of $143.82. At the end of the last trading period, Ecolab closed at $161.64. According to Northcoast Research, the prior rating for The Toro Co (NYSE:TTC) was changed from Neutral to Buy. For the third quarter, Toro had an EPS of $1.19, compared to year-ago quarter EPS of $0.92. The current stock performance of Toro shows a 52-week-high of $103.10 and a 52-week-low of $71.86. Moreover, at the end of the last trading period, the closing price was at $82.67. According to UBS, the prior rating for Newmont Corp (NYSE:NEM) was changed from Neutral to Buy. For the second quarter, Newmont had an EPS of $0.46, compared to year-ago quarter EPS of $0.83. The current stock performance of Newmont shows a 52-week-high of $86.37 and a 52-week-low of $40.27. Moreover, at the end of the last trading period, the closing price was at $41.67. Rosenblatt upgraded the previous rating for Nexstar Media Group Inc (NASDAQ:NXST) from Neutral to Buy. For the second quarter, Nexstar Media Group had an EPS of $5.56, compared to year-ago quarter EPS of $4.51. The current stock performance of Nexstar Media Group shows a 52-week-high of $204.62 and a 52-week-low of $148.10. Moreover, at the end of the last trading period, the closing price was at $191.31. For Inter & Co Inc (NASDAQ:INTR), Goldman Sachs upgraded the previous rating of Sell to Neutral. The current stock performance of Inter & Co shows a 52-week-high of $4.63 and a 52-week-low of $2.10. Moreover, at the end of the last trading period, the closing price was at $4.20. Morgan Stanley upgraded the previous rating for NextEra Energy Inc (NYSE:NEE) from Equal-Weight to Overweight. In the second quarter, NextEra Energy showed an EPS of $0.81, compared to $0.71 from the year-ago quarter. At the moment, the stock has a 52-week-high of $93.65 and a 52-week-low of $67.22. NextEra Energy closed at $85.11 at the end of the last trading period. According to Redburn Partners, the prior rating for PPG Industries Inc (NYSE:PPG) was changed from Neutral to Buy. For the second quarter, PPG Indus had an EPS of $1.81, compared to year-ago quarter EPS of $1.94. At the moment, the stock has a 52-week-high of $177.32 and a 52-week-low of $107.06. PPG Indus closed at $123.76 at the end of the last trading period. According to Stifel, the prior rating for Mettler-Toledo International Inc (NYSE:MTD) was changed from Hold to Buy. For the second quarter, Mettler-Toledo Intl had an EPS of $9.39, compared to year-ago quarter EPS of $8.10. The stock has a 52-week-high of $1699.11 and a 52-week-low of $1082.78. At the end of the last trading period, Mettler-Toledo Intl closed at $1195.02. For Perrigo Co PLC (NYSE:PRGO), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. Perrigo earned $0.43 in the second quarter, compared to $0.50 in the year-ago quarter. The stock has a 52-week-high of $43.90 and a 52-week-low of $31.32. At the end of the last trading period, Perrigo closed at $36.74. According to Wolfe Research, the prior rating for Tesla Inc (NASDAQ:TSLA) was changed from Peer Perform to Outperform. Tesla earned $0.76 in the second quarter, compared to $0.48 in the year-ago quarter. At the moment, the stock has a 52-week-high of $402.67 and a 52-week-low of $206.86. Tesla closed at $270.21 at the end of the last trading period. BTIG upgraded the previous rating for Transocean Ltd (NYSE:RIG) from Neutral to Buy. Transocean earned $0.10 in the second quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.56 and a 52-week-low of $2.32. Transocean closed at $3.56 at the end of the last trading period. BMO Capital upgraded the previous rating for Greif Inc (NYSE:GEF) from Underperform to Market Perform. Greif earned $2.35 in the third quarter, compared to $1.93 in the year-ago quarter. The stock has a 52-week-high of $72.80 and a 52-week-low of $53.65. At the end of the last trading period, Greif closed at $67.26. RBC Capital upgraded the previous rating for Rollins Inc (NYSE:ROL) from Sector Perform to Outperform. In the second quarter, Rollins showed an EPS of $0.20, compared to $0.20 from the year-ago quarter. The stock has a 52-week-high of $39.20 and a 52-week-low of $28.50. At the end of the last trading period, Rollins closed at $33.74. Jefferies upgraded the previous rating for Tsakos Energy Navigation Ltd (NYSE:TNP) from Hold to Buy. For the first quarter, Tsakos Energy Navigation had an EPS of $0.12, compared to year-ago quarter EPS of $0.71. The stock has a 52-week-high of $16.48 and a 52-week-low of $6.95. At the end of the last trading period, Tsakos Energy Navigation closed at $15.40. For Organon & Co (NYSE:OGN), Piper Sandler upgraded the previous rating of Neutral to Overweight. For the second quarter, Organon had an EPS of $1.25, compared to year-ago quarter EPS of $1.72. At the moment, the stock has a 52-week-high of $39.48 and a 52-week-low of $28.32. Organon closed at $28.50 at the end of the last trading period. For Frontline Ltd (NYSE:FRO), Jefferies upgraded the previous rating of Hold to Buy. In the second quarter, Frontline showed an EPS of $0.21, compared to $0.12 from the year-ago quarter. The current stock performance of Frontline shows a 52-week-high of $12.57 and a 52-week-low of $6.10. Moreover, at the end of the last trading period, the closing price was at $11.92. For Euronav NV (NYSE:EURN), Jefferies upgraded the previous rating of Hold to Buy. In the second quarter, Euronav showed an EPS of $0.02, compared to $0.44 from the year-ago quarter. The current stock performance of Euronav shows a 52-week-high of $17.24 and a 52-week-low of $7.91. Moreover, at the end of the last trading period, the closing price was at $16.23. See all analyst ratings upgrades. Downgrades For Signify Health Inc (NYSE:SGFY), William Blair downgraded the previous rating of Outperform to Market Perform. Signify Health earned $0.85 in the second quarter, compared to $0.00 in the year-ago quarter. The current stock performance of Signify Health shows a 52-week-high of $29.88 and a 52-week-low of $10.70. Moreover, at the end of the last trading period, the closing price was at $28.77. According to Dawson James, the prior rating for Arcimoto Inc (NASDAQ:FUV) was changed from Neutral to Sell. In the second quarter, Arcimoto showed an EPS of $0.39, compared to $0.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $8.27 and a 52-week-low of $1.93. Arcimoto closed at $2.00 at the end of the last trading period. JP Morgan downgraded the previous rating for Carlyle Secured ...Full story available on Benzinga.com
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.